Pharmaceutical composition (A) comprises an agent (B) that inhibits the activity or expression of a specific tumor-associated antigen (TAg) that is encoded by one of the following nucleic acids (NA): (a) any of 75 sequences (reproduced) or their fragments or derivatives； (b) a sequence that hybridizes to (a) under stringent conditions； (c) degenerate variants of (a) or (b)； or (d) a complement of (a)-(c). Independent claims are also included for the following: (1) similar composition (A1) containing an agent (B1) with tumor-inhibiting action selective for cells showing (abnormal) expression of TAg； (2) similar composition (A2) containing an agent (B2) that selectively increases the amount of complex formed between an HLA molecule and TAg (or part of it)； (3) pharmaceutical composition (A3) comprising TAg, NA, antibodies directed against TAg (or their fragments), antisense nucleic acid that hybridizes to NA, host cells that express TAg (or fragment), or isolated complexes of TAg with an HLA molecule； (4) method for diagnosing a disease associated with (abnormal) expression of TAg； (5) method for determining regression, progression and onset of a disease associated with (abnormal) expression of TAg； (6) several methods for treating diseases associated with (abnormal) expression of TAg； (7) method for treating, diagnosing and monitoring diseases associated with (abnormal) expression of TAg by administering an antibody, optionally linked to a therapeutic or diagnostic agent, that binds to TAg； (8) NA, or any nucleic acid that encodes the same proteins, as new compounds； (9) recombinant DNA or RNA containing the nucleic acid of (8)； (10) host cells that contain the nucleic acids of (8) or (9)； (11) proteins and polypeptides (P) encoded by the nucleic acids of (8), also their immunogenic fragments that bind to a human HLA receptor or human antibody； (12) agent (X) that binds specifically to (P), or part of it； (13) antibody (Ab) that binds selectively to a complex of (P),
